Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA.
Adv Exp Med Biol. 2019;1147:65-91. doi: 10.1007/978-3-030-16908-4_2.
Glioblastoma (GBM) is an aggressive and lethal disease that often results in a poor prognosis. Unlike most solid tumors, GBM is characterized by diffuse infiltrating margins, extensive angiogenesis, hypoxia, necrosis, and clonal heterogeneity. Recurrent disease is an unavoidable consequence for many patients as standard treatment options such as surgery, radiotherapy, and chemotherapy have proven to be insufficient in causing long-term survival benefits. Systemic delivery of promising drugs is hindered due to the blood-brain barrier and non-uniform perfusion within GBM tissue. In recent years, many investigations have highlighted the role of GBM stem cells (GSCs) and their microenvironment in the initiation and maintenance of tumor tissue. Preclinical and early clinical studies to target GSCs and microenvironmental components are currently underway. Of these strategies, immunotherapy using checkpoint inhibitors and redirected cytotoxic T cells have shown promising results in early investigations. But, GBM microenvironment is heterogenous and recent investigations have shown cell populations within this microenvironment to be plastic. These studies underline the importance of identifying the role of and targeting multiple cell populations within the GBM microenvironment which could have a synergistic effect when combined with novel therapies. Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression. Due to their role in regulating the blood-brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment. This chapter will introduce hallmarks of GBM and elaborate on the contributions of pericytes to these hallmarks by examining recent findings. In addition, the chapter also highlights the therapeutic value of targeting pericytes, while discussing conventional and novel GBM therapies and obstacles to their efficacy.
胶质母细胞瘤(GBM)是一种侵袭性和致命性疾病,通常预后不良。与大多数实体瘤不同,GBM 的特征是弥漫性浸润性边界、广泛的血管生成、缺氧、坏死和克隆异质性。对于许多患者来说,复发性疾病是不可避免的后果,因为手术、放疗和化疗等标准治疗方案已被证明不足以带来长期的生存获益。由于血脑屏障和 GBM 组织内灌注不均匀,有前途的药物的全身输送受到阻碍。近年来,许多研究强调了 GBM 干细胞(GSCs)及其微环境在肿瘤组织的发生和维持中的作用。目前正在进行针对 GSCs 和微环境成分的临床前和早期临床研究。在这些策略中,使用检查点抑制剂和重定向细胞毒性 T 细胞的免疫疗法在早期研究中显示出了有希望的结果。但是,GBM 微环境是异质的,最近的研究表明,这种微环境中的细胞群体具有可塑性。这些研究强调了确定 GBM 微环境中多个细胞群体的作用并针对这些细胞群体的重要性,当与新疗法结合使用时,这些细胞群体可能具有协同作用。周细胞是多能的血管周围细胞,在 GBM 微环境中通过协助肿瘤的发生、存活和进展发挥着至关重要的作用。由于它们在调节血脑屏障通透性、促进血管生成、肿瘤生长、为浸润性 GBM 细胞清除细胞外基质以及帮助 GBM 细胞逃避免疫监视方面的作用,周细胞可能是抑制或利用其在 GBM 微环境中的作用的理想治疗靶点。本章将介绍 GBM 的特征,并通过检查最近的发现,详细阐述周细胞对这些特征的贡献。此外,该章还突出了针对周细胞的治疗价值,同时讨论了传统和新型 GBM 疗法及其疗效的障碍。